A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis.

“Severity of spasticity in multiple sclerosis (MS) directly correlates with the level and cost of care required.

This study assessed whether a tetrahydrocannabinol/cannabidiol (THC/CBD) oromucosal spray for treatment of moderate-severe MS spasticity is a cost-effective use of healthcare resources in Wales.

The THC/CBD spray was found to be cost-effective for the treatment of spasticity in MS, and dominant, if home carer costs were included.

Use of THC/CBD has the potential to generate cost savings by significantly improving the symptoms of moderate to severe MS spasticity”

http://www.ncbi.nlm.nih.gov/pubmed/26750641

http://www.thctotalhealthcare.com/category/multiple-sclerosis-ms/